Capital Fund Management S.A. Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Capital Fund Management S.A.

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 13, 2025	BUY	$701.85 - $1046.91 $11.3 Million - $16.9 Million	16,100 New	16,100 $11.5 Million
Q1 2021 May 14, 2021	BUY	$446.73 - $548.2 $402,057 - $493,380	900 Added 8.57%	11,400 $5.39 Million
Q1 2020 May 13, 2020	SELL	$336.18 - $494.43 $605,124 - $889,974	-1,800 Reduced 14.63%	10,500 $5.13 Million
Q4 2019 Feb 13, 2020	SELL	$274.13 - $376.51 $3.78 Million - $5.2 Million	-13,800 Reduced 52.87%	12,300 $4.62 Million
Q3 2019 Nov 13, 2019	SELL	$273.46 - $318.39 $10.5 Million - $12.3 Million	-38,500 Reduced 59.6%	26,100 $7.24 Million
Q2 2019 Aug 12, 2019	BUY	$299.6 - $414.82 $15.4 Million - $21.3 Million	51,300 Added 385.71%	64,600 $20.2 Million
Q1 2019 May 13, 2019	SELL	$372.08 - $439.57 $3.8 Million - $4.48 Million	-10,200 Reduced 43.4%	13,300 $5.46 Million
Q4 2018 Feb 13, 2019	SELL	$335.82 - $403.04 $8.4 Million - $10.1 Million	-25,000 Reduced 51.55%	23,500 $8.78 Million
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $15.5 Million - $18 Million	-44,100 Reduced 47.62%	48,500 $19.6 Million
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $4.07 Million - $4.93 Million	14,300 Added 18.26%	92,600 $31.9 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $2.18 Million - $2.72 Million	6,900 Added 9.66%	78,300 $27 Million
Q4 2017 Feb 09, 2018	BUY	$358.63 - $469.95 $3.41 Million - $4.46 Million	9,500 Added 15.35%	71,400 $26.8 Million
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $26.7 Million - $31.2 Million	61,900	61,900 $27.7 Million

1,486

85.6M

1.53M

1.43M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $72.9B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.